Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.

Buzková H, Pechandová K, Danzig V, Vareka T, Perlik F, Zak A, Slanar O.

Med Sci Monit. 2012 Aug;18(8):CR512-517.

2.

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.

Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmöller J.

Clin Pharmacol Ther. 2003 Aug;74(2):186-94.

PMID:
12891229
3.
4.

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.

Ballantyne CM, Pazzucconi F, Pintó X, Reckless JP, Stein E, McKenney J, Bortolini M, Chiang YT.

Clin Ther. 2001 Feb;23(2):177-92.

PMID:
11293552
5.

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.

Betteridge DJ, Durrington PN, Fairhurst GJ, Jackson G, McEwan MS, McInnes GT, Miller JP, Mir MA, Reckless JP, Rees-Jones DI, et al.

Am J Med. 1994 Jun 6;96(6A):45S-54S.

PMID:
8017467
6.

Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.

Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, Shichiri M, Sakai T, Kono S, Arakawa K.

Int J Clin Pharmacol Ther. 1995 Jul;33(7):420-6.

PMID:
7582401
7.

Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.

Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013.

PMID:
18343245
8.

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

Olsson AG, Pauciullo P, Soska V, Luley C, Pieters RE, Broda G, Palacios B; Fluvastatin Study Group..

Clin Ther. 2001 Jan;23(1):45-61.

PMID:
11219479
10.

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.

Jacotot B, Benghozi R, Pfister P, Holmes D.

Am J Cardiol. 1995 Jul 13;76(2):54A-56A.

PMID:
7604799
11.

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.

Benesic A, Zilly M, Kluge F, Weissbrich B, Winzer R, Klinker H, Langmann P.

Infection. 2004 Aug;32(4):229-33.

PMID:
15293079
12.

Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.

Puccetti L, Bruni F, Bova G, Cercignani M, Palazzuoli A, Console E, Auteri A, Pasqui AL.

Nutr Metab Cardiovasc Dis. 2001 Dec;11(6):378-87.

PMID:
12055702
13.

Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.

Sasaki S, Nakagawa M, Nakata T, Endo N, Miyao K, Kitamura K, Fukuyama M, Kitani T, Yamada C.

Cardiology. 1997 Mar-Apr;88(2):160-5.

PMID:
9096917
14.

Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.

Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, Fischer JJ, Johnson BF, Theroux P, Jokubaitis L.

Ann Intern Med. 1994 Apr 1;120(7):537-43.

PMID:
8093139
15.
16.

Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.

Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrié A.

Pharmacogenomics. 2008 Sep;9(9):1217-27. doi: 10.2217/14622416.9.9.1217.

17.
18.

Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study).

Ilerigelen B, Uresin Y, San M, Kültürsay H, Güneri S, Serdar OA, Güleç S, Pençedemir H; TULIPS Investigators..

Curr Med Res Opin. 2007 May;23(5):1093-102.

PMID:
17519076
19.

Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.

Kim MJ, Nafziger AN, Kashuba AD, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS Jr.

Eur J Clin Pharmacol. 2006 Jun;62(6):431-6.

PMID:
16758259
20.

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.

Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D.

Am J Med. 1994 Jun 6;96(6A):69S-78S.

PMID:
8017470

Supplemental Content

Support Center